PF-02545920

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	6

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

trials per page:

Showing 1 to 6 of 6 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-004900-31-DE (EUCTR)	27/05/2015	13/02/2015	AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-0 ...	AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-0 ...	HUNTINGTON'S DISEASE MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's ...	Product Name: PF-02545920 INN or Proposed INN: not available Other descriptive name: PF-02545920	Pfizer Inc, 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: yes Male: yes	260	Phase 2	United States;Canada;Poland;Germany;United Kingdom
2	EUCTR2014-001291-56-GB (EUCTR)	24/04/2015	21/07/2014	A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND S ...	A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND S ...	HUNTINGTON’S DISEASE MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's ...	Product Code: PF-02545920 INN or Proposed INN: not available Other descriptive name: PF-02545920	Pfizer Inc., 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: yes Male: yes	260	Phase 2	United States;Canada;Poland;Germany;United Kingdom
3	NCT02342548 (ClinicalTrials.gov)	February 25, 2015	15/1/2015	Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 ...	An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-0 ...	Huntington's Disease	Drug: 20 mg BID of PF-02545920	Pfizer	NULL	Terminated	30 Years	66 Years	All	188	Phase 2	United States;Canada;Germany;Poland;United Kingdom
4	EUCTR2014-001291-56-DE (EUCTR)	27/10/2014	18/07/2014	A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND S ...	A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND S ...	HUNTINGTON’S DISEASE MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's ...	Product Code: PF-02545920 INN or Proposed INN: not available Other descriptive name: PF-02545920	Pfizer Inc, 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: yes Male: yes	260	Phase 2	United States;Canada;Poland;Germany;United Kingdom
5	NCT02197130 (ClinicalTrials.gov)	September 2014	16/7/2014	Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920In Subjects With Hunti ...	A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And S ...	Huntington's Disease	Drug: PF-02545920;Other: Placebo	Pfizer	NULL	Completed	30 Years	65 Years	All	272	Phase 2	United States;Canada;Germany;Poland;United Kingdom
6	NCT01806896 (ClinicalTrials.gov)	September 2013	6/3/2013	Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects Wi ...	A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate ...	Huntington's Disease	Drug: PF-02545920;Drug: Placebo	Pfizer	NULL	Completed	18 Years	70 Years	All	37	Phase 2	France

First Previous1Next Last